Starpharma Holdings Limited (FRA:PQ6)

Market Cap	91.61M
Revenue (ttm)	3.27M
Net Income (ttm)	-5.58M
Shares Out	n/a
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	214
Open	0.2040
Previous Close	0.1950
Day's Range	0.2040 - 0.2040
52-Week Range	0.0310 - 0.2380
Beta	n/a
RSI	55.08
Earnings Date	Feb 26, 2026

About Starpharma Holdings

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company’s products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It also involved in the development of a dendrimer-enhance...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1997
• Employees: 40
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PQ6

Financial Performance

In 2025, Starpharma Holdings's revenue was 5.85 million, a decrease of -40.04% compared to the previous year's 9.76 million. Losses were -9.99 million, 22.4% more than in 2024.

Financial numbers in AUD